TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Zevra Therapeutics ( (ZVRA) ).
On November 20, 2025, Zevra Therapeutics announced that its Chief Financial Officer, R. LaDuane Clifton, will resign effective December 31, 2025, to pursue other opportunities. Clifton, who joined the company in 2015, played a key role in its transition to a commercial-stage company and leaves behind a strong financial foundation. The company has initiated a search for his successor.
The most recent analyst rating on (ZVRA) stock is a Hold with a $9.50 price target. To see the full list of analyst forecasts on Zevra Therapeutics stock, see the ZVRA Stock Forecast page.
Spark’s Take on ZVRA Stock
According to Spark, TipRanks’ AI Analyst, ZVRA is a Neutral.
Zevra Therapeutics’ overall stock score reflects strong revenue growth and strategic advancements, particularly with MIPLYFFA. However, challenges in profitability, cash flow, and technical indicators weigh down the score. The robust financial position and reasonable valuation provide some support.
To see Spark’s full report on ZVRA stock, click here.
More about Zevra Therapeutics
Zevra Therapeutics, Inc. is a commercial-stage company dedicated to addressing unmet needs in the treatment of rare diseases. The company employs unique, data-driven development and commercialization strategies to overcome complex drug development challenges, aiming to provide life-changing therapeutics to the rare disease community.
Average Trading Volume: 1,867,470
Technical Sentiment Signal: Buy
Current Market Cap: $545M
For a thorough assessment of ZVRA stock, go to TipRanks’ Stock Analysis page.